Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
It is a $187B healthcare company. Revenue grew 5.5% over the last year, it currently loses money, and its net debt equals ~1.9 years of free cash flow.
- Website
- gilead.com
- Location
- Foster City, CA
- Employees
- 17 000
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong moat; Growth, Profitability and Health lag behind.
Valuation64
- P/E vs own history22th pct · 20/25
- FCF yield6.9% · 20/25
- P/S6.2x · 12/25
- EV/EBITDA19.3x · 12/25
Growth48
- Revenue CAGR1.9% · 6/25
- Net income CAGR8.1% · 12/25
- EPS CAGR ~5Y133.6% · 25/25
- Fwd implied growth0.0% · 5/25
Profitability20
- ROIC17.9% · 20/25
- ROE-16.3% · 0/25
- Net margin-10.6% · 0/25
- Operating margin-8.2% · 0/25
Health42
- Altman Zn/a · 0/25
- Current ratio1.27 · 12/25
- Interest coverage44.7x · 25/25
- Net cash / debtD/A 42% · 5/25
Quality50
- Piotroski F8/9 · 25/25
- Beneish M-2.55 · 25/25
- FCF conversionn/a · 0/25
- Margin stabilityσ 26.9% · 0/25
Moat82
- ROIC >12% years8/10 yrs · 20/25
- Median gross margin79.0% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 0.5% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2020AcquisitionGilead announced it had reached a deal to acquire Immunomedics for $21 billion ($88 per share),…
- FY2018FinancialBecame debt-freecash now exceeds total debt
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $10B$30.4B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- FY2016FinancialBest year on record$13.5B net income
- 2011AcquisitionThe company acquired Calistoga Pharmaceuticals for ($225 million plus milestone payments)
- 2009AcquisitionThe company acquired CV Therapeutics, Inc. for $1.4 billion, bringing Ranexa and Lexiscan into Gilead
- 2009MilestoneRiordan also recruited scientific advisers, including Harold Varmus, a Nobel laureate who later became Director of…
- 2006AcquisitionGilead purchased Raylo Chemicals, Inc. in November 2006, for a price of
- 2002AcquisitionGilead and Triangle Pharmaceuticals announced that Gilead would acquire Triangle for around $464…
- 1999AcquisitionGilead acquired NeXstar Pharmaceuticals of Boulder, Colorado
- 1996ProductGilead launched Vistide (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis in…
- 1992IPOGilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that…
- 1992ProductGilead debuted on the NASDAQ in January 1992
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (79.6%)
- Strong cash conversion — FCF is 42.5% of revenue
- Interest covered 44.7× by operating earnings
- High returns on invested capital (ROIC 17.9%)
- Piotroski F-Score 8/9 — fundamentally strong checklist
Watch-outs
- Not profitable — 10.6% net margin
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+5.5% YoY
- Profitable — makes more than it spends-$3.24B TTM
- Profit growing — earnings are higher than last year+23.1% YoY
- Generates cash — cash left after running and investing$12.9B TTM
- Debt under control — could handle its obligations~1.9y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$187B market cap
- Not printing shares — share count not ballooning — you keep your slice-0.6% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 37/100
- Pays a dividend — returns cash to shareholdersyield 3.24%
- Valuation not extreme — price not wildly above earningsP/E 22.0
Peer comparisonGilead Sciences Inc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| GILD this company | $187.5B | 22.0 | +5.5% | -10.6% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: GILD vs LLY · GILD vs JNJ · GILD vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/GILD
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of GILD on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $151.20 · market cap $187B.